Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong · Delayed Price · Currency is HKD 2.540
-0.035 (-1.36%)
Aug 27, 2026, 11:56 AM HKT
HKG:1349 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 667.94 | 685.8 | 709.4 | 850.73 | 1,031 | 1,140 |
Other Revenue | - | - | - | - | - | 0.5 |
| 667.94 | 685.8 | 709.4 | 850.73 | 1,031 | 1,140 | |
Revenue Growth | -3.39% | -3.33% | -16.61% | -17.50% | -9.57% | 36.76% |
Cost of Revenue | 62.05 | 70.83 | 63.46 | 74.08 | 86.29 | 81.02 |
Gross Profit | 605.89 | 614.96 | 645.95 | 776.66 | 944.87 | 1,059 |
Selling, General & Admin | 412.45 | 435.54 | 341.04 | 426.45 | 599.5 | 660.26 |
Research & Development | 313.99 | 357.94 | 314.16 | 243.76 | 226.85 | 224.39 |
Other Operating Expenses | 14.17 | 5.16 | 7.44 | 5.39 | 6.84 | 6.15 |
Operating Expenses | 739.38 | 774.83 | 653.7 | 699.5 | 830.78 | 896.57 |
Operating Income | -133.49 | -159.87 | -7.75 | 77.15 | 114.09 | 162.72 |
Interest Expense | -0.7 | -0.66 | -0.59 | -3.07 | -1.54 | -1.06 |
Interest & Investment Income | - | 2.81 | 5.55 | 7.97 | 11.29 | 25.89 |
Currency Exchange Gain (Loss) | 0.12 | 0.12 | 0.15 | -1.08 | -0.83 | 0.14 |
Other Non Operating Income (Expenses) | 0.06 | 0.02 | -0.07 | -0.3 | -0.14 | 6.21 |
EBT Excluding Unusual Items | -134.01 | -157.58 | -2.71 | 80.68 | 122.88 | 193.91 |
Gain (Loss) on Sale of Investments | -9.85 | -9.85 | -10.41 | -4.35 | -1.28 | - |
Gain (Loss) on Sale of Assets | 0.03 | 0.22 | 0.03 | 0.3 | 1.92 | 1.78 |
Asset Writedown | -0.07 | - | -3.93 | -5 | -1.83 | -2.15 |
Other Unusual Items | 19.21 | 11.36 | 22.48 | 25.9 | 10.61 | 22.38 |
Pretax Income | -124.69 | -155.85 | 5.46 | 97.53 | 132.29 | 215.92 |
Income Tax Expense | 1.87 | 1.87 | -33.98 | -10.92 | -4.98 | 3.54 |
Earnings From Continuing Operations | -126.57 | -157.72 | 39.43 | 108.45 | 137.27 | 212.38 |
Minority Interest in Earnings | 0.31 | 0.28 | 0.3 | 0.18 | 0.72 | 0.92 |
Net Income | -126.26 | -157.44 | 39.73 | 108.63 | 138 | 213.3 |
Net Income to Common | -126.26 | -157.44 | 39.73 | 108.63 | 138 | 213.3 |
Net Income Growth | - | - | -63.42% | -21.28% | -35.30% | 29.54% |
Shares Outstanding (Basic) | 1,037 | 1,037 | 1,037 | 1,034 | 1,030 | 1,041 |
Shares Outstanding (Diluted) | 1,037 | 1,037 | 1,037 | 1,034 | 1,031 | 1,045 |
Shares Change | - | - | 0.23% | 0.29% | -1.29% | 5.59% |
EPS (Basic) | -0.12 | -0.15 | 0.04 | 0.11 | 0.13 | 0.20 |
EPS (Diluted) | -0.12 | -0.15 | 0.04 | 0.11 | 0.13 | 0.20 |
EPS Growth | - | - | -63.51% | -19.19% | -35.00% | 20.17% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 138.99 | 109.03 | -59.18 | -27.95 | 77.96 | 148.78 |
Free Cash Flow Per Share | 0.13 | 0.10 | -0.06 | -0.03 | 0.08 | 0.14 |
Dividend Per Share | - | - | 0.050 | 0.070 | 0.070 | 0.070 |
Dividend Growth | - | - | -28.57% | 0% | 0% | 40.00% |
Gross Margin | 90.71% | 89.67% | 91.05% | 91.29% | 91.63% | 92.90% |
Operating Margin | -19.98% | -23.31% | -1.09% | 9.07% | 11.06% | 14.27% |
Profit Margin | -18.90% | -22.96% | 5.60% | 12.77% | 13.38% | 18.70% |
Free Cash Flow Margin | 20.81% | 15.90% | -8.34% | -3.29% | 7.56% | 13.05% |
EBITDA | -84.86 | -104.9 | 58.53 | 129.05 | 186.92 | 216.5 |
EBITDA Margin | -12.70% | -15.30% | 8.25% | 15.17% | 18.13% | 18.99% |
D&A For EBITDA | 48.63 | 54.97 | 66.28 | 51.89 | 72.83 | 53.78 |
EBIT | -133.49 | -159.87 | -7.75 | 77.15 | 114.09 | 162.72 |
EBIT Margin | -19.98% | -23.31% | -1.09% | 9.07% | 11.06% | 14.27% |
Effective Tax Rate | - | - | - | - | - | 1.64% |